Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Home Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

/ Publications

Share the Post

About the Author

Related Posts

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
Read More
Bryan Ball
Pacific pride: Abraxis veteran grooms dormant Celgene drug for success
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement

Comments

Comments are closed.